Immunicum AB (publ) Initiates Trading of Shares on Nasdaq Stockholm
January 15 2018 - 2:45AM
YASTESTPress Release
15 January 2018
Immunicum AB (publ) Initiates Trading of Shares on Nasdaq Stockholm
Immunicum AB
(publ), a biopharmaceutical company advancing a novel
immuno-oncology treatment against a range of solid tumors, today
announced the trading of its shares (IMMU.ST) on the main market of
Nasdaq Stockholm. Immunicum is listed as a small cap company within
the healthcare sector.
"We welcome Immunicum AB to Nasdaq
Stockholm's main market and our expanding healthcare sector. We
look forward to seeing the company's further growth and development
supported by increased investor visibility and international
exposure within the life science financial community," said Adam
Kostyál, Head of European listings at Nasdaq.
"We are enthusiastic about our
uplisting onto the main market of Nasdaq Stockholm which marks the
achievement of an important strategic objective for the company,"
said Carlos de Sousa, CEO of Immunicum. "Immunicum has made
significant progress in the past year by further validating
ilixadencel through positive clinical and preclinical data. We have
also strengthened our management team, increased awareness of the
company and raised the capital needed to reach the next value
inflection point in ilixadencel's development. The uplisting
combined with these accomplishments emphasize our ongoing
commitment to developing ilixadencel into a new treatment for
cancer."
For more information, please
contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Investor Relations Sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: +46 709 71 12 53
E-mail: ir@immunicum.com
Investor and Media Relations
EU/US
Gretchen Schweitzer
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
About Immunicum AB (publ) Immunicum is establishing a
unique immuno-oncology approach through the development of
allogeneic, off-the-shelf cell-based therapies. Our goal is to
improve survival outcomes and quality of life by priming the
patient's own immune system to fight cancer. The company's lead
product ilixadencel, consisting of pro-inflammatory allogeneic
dendritic cells, has the potential to become a backbone component
of modern cancer combination treatments in a variety of solid tumor
indications. Founded and based in Sweden, Immunicum is publicly
traded on the Nasdaq Stockholm. www.immunicum.com |
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024